Spectrum Pharma (SPPI) Tops Q3 EPS by 8c

Spectrum Pharma (NASDAQ: SPPI) reported Q3 EPS of ($0.27), $0.08 better than the analyst estimate of ($0.35).

“The third quarter was marked by significant progress in our drug development programs and a strengthened financial position,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “Our team is preparing for the upcoming pre-NDA meeting with the FDA for poziotinib and actively working to obtain an approval for ROLONTIS as soon as possible.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Z Squared outlines AI power strategy and Paradox Data acquisition
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c